CenExel Celebrates FDA Approval of JOURNAVX(TM), a Groundbreaking Non-Opioid Pain Treatment
SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...
BioSpace3d
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
fingerlakes12d
FDA approves first new non-opioid painkiller in 20 years
The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...
rheumatologyadvisor6d
Journavx, a Nonopioid Oral Pain Medication, Gets FDA Approval
The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.
Newsday6d
Experts: Journavx a prescription to stem Long Island's addiction crisis
The FDA approved Journavx on Thursday following a pair of clinical trials on 874 participants with moderate to severe acute pain following abdominoplasty — commonly known as a "tummy tuck ...
EURweb on MSN6d
FDA Approves New Non-Opioid Painkiller Journavx for Acute Pain | Watch
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
Gulf Shores pharmacist sees promise in FDA-approved nonaddictive pain medicine Journavx
For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...
Yale Daily News4d
First FDA-approved non-addictive painkiller has Yale roots
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
Pharmabiz2d
CenExel announces its role in Vertex Pharma’s studies in Journavx and celebrates US FDA approval
CenExel, a leading network of clinical research sites, congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the US FDA approval of Journavx ...